Current Opinion in HIV and AIDS

Scope & Guideline

Highlighting trends that shape the future of health.

Introduction

Explore the comprehensive scope of Current Opinion in HIV and AIDS through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Current Opinion in HIV and AIDS in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1746-630x
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2007 to 2024
AbbreviationCURR OPIN HIV AIDS / Curr. Opin. HIV AIDS
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The journal 'Current Opinion in HIV and AIDS' aims to provide a comprehensive overview of the latest developments in the field of HIV research, focusing on both clinical and basic science. The scope encompasses a variety of interdisciplinary approaches to understand HIV infection, its treatment, and related comorbidities.
  1. Microbiome and HIV Interactions:
    A core focus of the journal is the examination of the microbiome's role in HIV infection and disease progression, including its impact on transmission dynamics and therapeutic strategies.
  2. Innovative Therapeutic Strategies:
    The journal consistently highlights advancements in therapeutic approaches, including immunotherapy, gene therapy, and novel drug delivery systems, aimed at achieving HIV remission and eradication.
  3. HIV Comorbidities and Public Health:
    Research on the intersection of HIV with other health conditions, particularly chronic diseases like obesity and cardiovascular issues, is a critical area of focus, underscoring the need for comprehensive patient care.
  4. Vaccine Development and Prevention Strategies:
    The journal emphasizes the ongoing efforts in HIV vaccine research and prevention strategies, exploring both traditional and novel methodologies to enhance vaccine efficacy.
  5. Social and Behavioral Aspects of HIV:
    A significant aim is to address the social determinants of health and behavioral sciences in HIV prevention and care, recognizing the importance of contextual factors in addressing the HIV epidemic.
The journal has identified several emerging themes that reflect the latest trends in HIV research, highlighting innovative approaches and interdisciplinary collaborations.
  1. Microbiome Research:
    Recent publications reveal a growing interest in understanding the microbiome's influence on HIV risk, disease progression, and therapeutic outcomes, showcasing its potential as a target for intervention.
  2. Immunotherapy and Novel Treatment Approaches:
    There is an upward trend in research focusing on immunotherapy, including CAR-T cells and therapeutic vaccines, as promising strategies for achieving long-term HIV control and potential cures.
  3. Intersection of HIV with Other Epidemics:
    Research examining the interplay between HIV and other global health issues, such as COVID-19, is on the rise, reflecting a need for integrated responses to multiple public health challenges.
  4. Long-Acting Antiretroviral Therapies:
    The development and implementation of long-acting formulations for HIV treatment and prevention are increasingly prominent, suggesting a shift towards patient-centered care and adherence strategies.
  5. Social Determinants of Health in HIV:
    There is a growing emphasis on the social and behavioral determinants of health as critical components in addressing HIV prevention and treatment, highlighting the importance of context in health outcomes.

Declining or Waning

While the journal has a broad and evolving scope, certain themes have shown a decline in focus over the years, reflecting shifts in research priorities and advancements in the field.
  1. Traditional Antiretroviral Therapies:
    There is a noticeable decrease in publications focusing solely on traditional antiretroviral therapies, as research shifts towards more innovative treatment modalities and strategies for HIV eradication.
  2. HIV Criminalization and Legal Issues:
    Research concerning the legal aspects of HIV, including criminalization, has become less prevalent, possibly due to a growing emphasis on public health approaches rather than punitive measures.
  3. Focus on HIV in Isolation:
    The journal has moved away from studies that treat HIV as a standalone issue, increasingly integrating discussions about comorbidities and the broader health context in which HIV occurs.

Similar Journals

AIDS Research and Treatment

Pioneering insights in HIV/AIDS care.
Publisher: HINDAWI LTDISSN: 2090-1240Frequency: 1 issue/year

AIDS Research and Treatment is a premier open access journal published by HINDAWI LTD, dedicated to advancing the understanding and treatment of HIV/AIDS and related conditions. Launched in 2010, the journal has established itself as a vital resource for researchers, healthcare professionals, and students in the fields of Dermatology, Immunology, Infectious Diseases, and Public Health. With a notable 2023 impact factor reflected in its Q2 and Q3 quartile rankings across key medical categories, the journal plays a critical role in disseminating high-quality research and fostering innovation in the prevention and treatment of AIDS. It provides a wide range of open access options, enabling easier dissemination and increased visibility of research findings globally. As the landscape of HIV/AIDS research continues to evolve, AIDS Research and Treatment remains at the forefront, ensuring crucial insights and developments are shared to enhance public health outcomes.

ACS Infectious Diseases

Fostering Breakthroughs in Infectious Disease Understanding
Publisher: AMER CHEMICAL SOCISSN: 2373-8227Frequency: 12 issues/year

ACS Infectious Diseases is a premier journal in the field of infectious diseases, published by the American Chemical Society. With an impressive Impact Factor that places it in the Q1 category for Infectious Diseases in 2023, the journal serves as an essential resource for researchers, healthcare professionals, and students dedicated to the study of infectious agents and their impact on public health. Established in 2015, the journal is committed to publishing cutting-edge research that enhances our understanding of infectious diseases and fosters the development of innovative interventions. Although not an open access journal, it provides a platform for high-quality research that influences policies and practices in the field. With an address located at 1155 16TH ST, NW, WASHINGTON, DC 20036, ACS Infectious Diseases is an authoritative voice in advancing the science and practice of infectious disease management.

BIOMEDICINE & PHARMACOTHERAPY

Pioneering insights for better health outcomes.
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 0753-3322Frequency: 12 issues/year

BIOMEDICINE & PHARMACOTHERAPY is a distinguished journal published by Elsevier France - Éditions Scientifiques Médicales Elsevier, specializing in the essential fields of medicine and pharmacology. Established in 1982 and covering literature up to 2024, this journal is notably recognized for its impact, holding a prestigious Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, as well as a commendable position within the top 10% of its category based on Scopus rankings. Researchers and practitioners will find it serves as a vital resource for the latest advancements, innovations, and critical reviews in the life sciences and therapeutic practices. The journal emphasizes rigorous peer review and high-quality publications, aimed at facilitating knowledge dissemination in biomedicine and pharmacotherapy. Its commitment to excellence makes it an indispensable platform for contributors and readers alike who are engaged in improving health outcomes through pharmaceutical research and medical advances.

Lancet HIV

Transforming public health through cutting-edge HIV research.
Publisher: ELSEVIER INCISSN: 2352-3018Frequency: 12 issues/year

The Lancet HIV, published by Elsevier Inc in the United Kingdom, stands at the forefront of HIV research and public health, providing a vital platform for the dissemination of innovative findings and critical knowledge in the fields of epidemiology, immunology, infectious diseases, and virology. With its prestigious Q1 rankings in the aforementioned categories for 2023, the journal is recognized for its significant contribution to advancing understanding and addressing challenges posed by HIV globally. Its impressive standing, including a Scopus ranking in the 94th percentile for multiple categories, underscores its impact within the research community. The Lancet HIV publishes rigorously peer-reviewed research articles, reviews, and opinion pieces, ensuring that all stakeholders—researchers, practitioners, and policymakers—are engaged with up-to-date, evidence-based perspectives. Researchers and students alike will find this journal an invaluable resource for enhancing their knowledge and contributing to the ongoing discourse surrounding HIV treatment and prevention.

Translational Research

Advancing Health Through Innovative Research
Publisher: ELSEVIER SCIENCE INCISSN: 1931-5244Frequency: 12 issues/year

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

AIDS RESEARCH AND HUMAN RETROVIRUSES

Illuminating Pathways in AIDS Research
Publisher: MARY ANN LIEBERT, INCISSN: 0889-2229Frequency: 12 issues/year

AIDS RESEARCH AND HUMAN RETROVIRUSES, published by Mary Ann Liebert, Inc., is a pivotal journal dedicated to advancing the field of HIV research and the broader spectrum of human retroviruses. With an ISSN of 0889-2229 and an E-ISSN of 1931-8405, this journal has been in continuous publication since 1987 and is respected in the academic community for its rigorous peer-reviewed articles. As a Q3 ranked journal in Immunology, Infectious Diseases, and Virology as of 2023, it plays a crucial role in disseminating cutting-edge research, theoretical advancements, and clinical insights that contribute significantly to the understanding and treatment of HIV and related disorders. The journal's objective is to foster collaboration among researchers, healthcare professionals, and educators by providing a platform for the exchange of innovative ideas and findings. Although not an open-access journal, its compelling content ensures that it remains a primary resource for those in the academic and medical communities tackling the challenges posed by retroviral infections. With a commitment to excellence and relevance, AIDS RESEARCH AND HUMAN RETROVIRUSES continues to shape the future of research in this critical area.

AJAR-African Journal of AIDS Research

Pioneering Research in the Fight Against AIDS
Publisher: TAYLOR & FRANCIS LTDISSN: 1608-5906Frequency: 4 issues/year

AJAR - African Journal of AIDS Research, an esteemed publication by Taylor & Francis Ltd, stands at the forefront of research in the field of HIV/AIDS, with a specific focus on the African continent. Established in 2003 and publishing continuously through 2024, this journal serves as a crucial platform for disseminating innovative research findings aimed at addressing the challenges of HIV/AIDS. With its ISSN 1608-5906 and E-ISSN 1727-9445, AJAR is indexed in prominent databases and holds a respectable Q3 rating in major categories such as Infectious Diseases, Medicine, Public Health, and Virology as of 2023. This positions the journal as a relevant resource for scholars and medical professionals looking to stay informed on the latest developments and strategies in AIDS research. Although it is not currently an open-access journal, AJAR provides readers with valuable insights that are essential for advancing public health initiatives and infectious disease research across Africa and beyond. The journal's commitment to high-quality peer-reviewed research underscores its importance within its field, making it a vital resource for researchers, students, and policymakers alike.

AIDS REVIEWS

Illuminating the path to better health outcomes.
Publisher: PERMANYER PUBLISSN: 1139-6121Frequency: 4 issues/year

AIDS REVIEWS, published by Permanyer Publishing, is a distinguished academic journal dedicated to providing comprehensive insights into the field of AIDS research. Since its inception in 2000, the journal has served as a vital platform for disseminating knowledge on various aspects of HIV/AIDS, including prevention, treatment advancements, and socio-medical implications. With a commendable Q3 ranking in both Infectious Diseases and Medicine (miscellaneous), as well as Pharmacology (medical) in 2023, the journal has made significant strides in the academic community, covering relevant topics and emerging trends up to 2024. Although not open access, AIDS REVIEWS continues to attract contributions from leading researchers and professionals, fostering a collaborative environment aimed at improving health outcomes related to AIDS. Located in Barcelona, Spain, this journal is an essential resource for anyone dedicated to advancing their understanding of this global health challenge.

Annals of Geriatric Medicine and Research

Unlocking the potential of geriatric studies.
Publisher: KOREAN GERIATRIC SOCISSN: 2508-4909Frequency: 4 issues/year

Annals of Geriatric Medicine and Research, published by the Korean Geriatric Society, is a premier open-access journal dedicated to advancing the understanding of geriatric medicine and gerontology. Since its inception in 1997, the journal has played a crucial role in disseminating significant research findings, policy discussions, and clinical innovations that address the complexities of elderly healthcare. Based in South Korea, the journal has gained recognition with an impact factor reflecting its Q2 ranking in the field of Geriatrics and Gerontology for 2023, placing it competitively within its category among 116 journals. Researchers, healthcare professionals, and students will find comprehensive insights ranging from clinical studies to public health strategies crucial for enhancing the quality of life of older adults. With a commitment to open access, the journal ensures that its valuable information is freely available, fostering collaboration and knowledge-sharing that is vital in this dynamic field.

MICROBES AND INFECTION

Championing Open Access for Microbial Insights
Publisher: ELSEVIERISSN: 1286-4579Frequency: 12 issues/year

MICROBES AND INFECTION is a premier academic journal published by Elsevier, dedicated to the dynamic fields of immunology, infectious diseases, and microbiology. With a notable impact factor reflective of its high-quality research contributions, the journal is categorized in the Q2 quartile across these fields as of 2023. Based in France and operating since 1999, MICROBES AND INFECTION offers a platform for researchers, professionals, and students to disseminate and access cutting-edge findings that drive innovation and knowledge in microbial and infectious disease research. The journal is ranked impressively within the Scopus database, securing ranks such as #16 in Microbiology and #33 in Infectious Diseases, underscoring its high relevance in the scientific community. Subscribers to the journal can expect an array of articles, reviews, and original research, all designed to advance understanding and improve clinical practices in the fight against infectious agents. With its ongoing commitment to open access options, MICROBES AND INFECTION continues to foster global collaboration and information sharing in the pursuit of addressing pressing microbiological challenges.